凱普生物(300639.SZ)一季度淨利潤預增10.07%-25.3%
格隆匯4月9日丨凱普生物(300639.SZ)公佈,預計2020年第一季度歸屬於上市公司股東的淨利潤1880萬元-2140萬元,同比增長10.07%-25.30%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1665萬元-1925萬元,同比增長11.24%-28.61%。
報告期內,因新型冠狀病毒傳染疫情爆發,公司HPV檢測等業務受到一定的影響。基於疫情防控需要,公司組織科研力量投入新冠核酸檢測產品開發,公司第三方實驗室積極響應各地需求,開展新冠核酸檢測服務,投入到抗擊疫情的工作中。報告期內,公司營業收入對比去年同期略有增長。
報告期內,預計非經常性損益對公司淨利潤的影響金額約為215萬元,對本期盈利沒有重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.